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Abstract 
Introduction: Hepatitis C virus (HCV) infections remain an increasingly prevalent and 
emergent health problem worldwide, causing a wide spectrum of liver diseases. Combination 
therapy with pegylated interferon (PEG-IFN) of peginterferon alfa-2a and oral ribavirinis 
currently recognized as the standard treatment of chronic HCV infection. Several complex 
immunological mechanisms are involved during the course of HCV treatment using 
interferons. The role of endogenous interferon gamma (IFNγ) in Egyptian patients infected 
with chronic HCV and treated with PEG-IFN/ribavirin is uncertain. The goal of this study 
was to evaluate the association of IFNγ and chronic HCV infection among patients treated 
with combination therapy of PEG-IFN/ribavirin. Methodology: Samples from 20 patients 
infected with HCV genotype-4 (HCV-4) and 20 non-infected individuals as healthy controls 
were used in this retrospective study. IFNγ levels in peripheral blood monocytes were 
analyzed, along with liver enzyme alanine aminotransferase (ALT) levels, and single 
nucleotide polymorphism (SNP) of the myxovirus resistance-A (MxA) gene. Results: The 
results showed that an increase of IFNγ and a decrease of ALT levels in chronic HCV-
infected patients after 12 weeks of treatment with combination therapy. Conclusion: 
Enhanced IFNγ secretion and decreased liver enzyme ALT production are indicative of HCV 
clearance and improvement of liver function. In addition, the SNP of the MxA gene is an 
important host genetic factor that independently influenced the response to IFNα in patients 
with chronic HCV infection, especially in those with a low viral load. 
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